CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non‐small cell lung cancer in vitro and in vivo

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non‐small cell lung cancer in vitro and in vivo

Abstract Background CM082 is a novel angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR) and platelet‐derived growth factor receptor (PDGFR). The purpose of this research was to evaluate the antitumor activity of CM082 combined with gefitinib on epidermal growth fact...

Full description

Bibliographic Details
Main Authors: Kun Zhang, Lili Wang, Aili Wei, Xinfei Jia, Xiaoqing Liu
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Thoracic Cancer
Subjects:
Angiogenesis inhibitor
combination therapy
gefitinib
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13430

Similar Items

Similar Items